默茨制药的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 2 条
2024
FDA对Xeomin Instagram广告发出警告
美国食品药品监督管理局对一则由Nate Berkus出演的与Xeomin相关的Instagram广告提出异议。该机构表示，关于产品快速效果和独特益处的声明缺乏足够的支持证据，且风险信息的呈现不足，使沟通具有误导性。
2021
Merz就仿制Cuvposa申请起诉MSN
提起诉讼
Merz Pharmaceuticals起诉MSN Pharmaceuticals，指称MSN申请销售Merz药品Cuvposa的仿制药将侵犯其药品专利。Merz请求法院禁止该仿制产品的商业制造、使用、销售、要约销售或进口。
来源摘录
On Thursday, Merz Pharmaceuticals LLC (Merz) filed a complaint against fellow pharmaceutical company MSN Pharmaceuticals Inc. (MSN) for allegedly infringing its drug patent by seeking to make a generic version of Merz’s drug Cuvposa.
The plaintiff requests that its accusation of infringement is affirmed and that there is an injunction enjoining MSN, and all persons acting in concert with MSN, from the commercial manufacture, use, sale, offer for sale, or importation into the United States of MSN’s ANDA Products, or any other drug product whose use is covered by the patent.